Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans

scientific article

Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1124/DMD.115.066282
P8608Fatcat IDrelease_d4h37lwjhzaxfksumgtgpvb5oq
P698PubMed publication ID26451002

P2093author name stringSusan Wong
Yuzhong Deng
Shuguang Ma
Luna Musib
Cornelis E C A Hop
Edna F Choo
Isabelle Rooney
Jason Halladay
Mark J Dresser
Mary Gates
Ryan H Takahashi
S Cyrus Khojasteh
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectcobimetinibQ15708292
P304page(s)28-39
P577publication date2015-10-08
P1433published inDrug Metabolism and DispositionQ1261140
P1476titleAbsorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans
P478volume44

Reverse relations

cites work (P2860)
Q50911347Absorption, metabolism and excretion of cobimetinib, an oral MEK inhibitor, in rats and dogs
Q38777596Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma
Q91723015Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
Q38783292Cobimetinib and vemurafenib for the treatment of melanoma
Q97647941Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics
Q39735712Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation
Q38937228Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.
Q98155148RAS/MAPK Pathway Driver Alterations Are Significantly Associated with Oncogenic KIT Mutations in Germ-cell Tumors
Q38836158Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review
Q59793997Reviewing the role of healthy volunteer studies in drug development
Q23923997Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting
Q64055352Targeting the ERK Signaling Pathway in Melanoma
Q56365831Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review

Search more.